In a high proportion of human carcinomas overexpression of the EGFR (epidermal growth factor receptor), a receptor tyrosine kinase, represents a potential target for cancer treatment. EGFR is induced to dimerize through ligand binding which activates the tyrosine kinase activity of the receptor. This catalyses the transfer of ATP's γ-phosphate to hydroxyl groups of tyrosine residues on the receptor, creating binding sites that recruit downstream signalling proteins. New drugs, SMTKIs (small-molecule tyrosine kinase inhibitors), have been designed to inhibit the tyrosine kinase activity of the receptor, producing an anti-tumour effect. The development of surrogate markers to determine the drug activity of these new inhibitors would be of great benefit in drug evaluation and in the subsequent management of patient disease. This review describes current treatments of cancer using tyrosine kinase inhibitors and the use of proteomic analysis to identify possible markers of activity of these new drugs.
Conference Article| December 01 2003
Identification of surrogate markers for determining drug activity using proteomics
Biochem Soc Trans (2003) 31 (6): 1488–1490.
- Views Icon Views
- Share Icon Share
C.M. McClelland, W.J. Gullick; Identification of surrogate markers for determining drug activity using proteomics. Biochem Soc Trans 1 December 2003; 31 (6): 1488–1490. doi: https://doi.org/10.1042/bst0311488
Download citation file: